Instalab
logoInstalab

Lactobacillus Vaginalis

Vaginal Swab Test
Get an early read on your vaginal microbiome balance, beyond what a standard infection test can show.
4.9 (4,102 reviews)
Tested by US Biotek Laboratories
Physician-reviewed results
How it works
Order from Instalab
No prescription or your own doctor's order needed
Collect your sample
At home
Get results
Explained with clear next steps, no medical jargon

Should you take a Lactobacillus Vaginalis test?

This test is most useful if any of these apply to you.

Dealing With Recurrent Vaginal Symptoms
This swab can reveal whether your microbiome keeps tipping toward dysbiosis, even when standard wet mount results look normal.
Planning or Going Through Pregnancy
Low Lactobacillus during pregnancy has been linked to higher preterm birth risk, and this swab can flag the pattern early enough to act on.
Trying to Conceive or Doing IVF
Your vaginal microbiome composition is linked to implantation and live birth rates, and this swab gives you data ahead of treatment cycles.
Tracking HPV or Abnormal Pap Findings
Lactobacillus depletion has been linked to slower clearance of HPV and cervical lesions, so this swab adds context to your cervical screening.

About Lactobacillus Vaginalis

Your vagina is home to a community of bacteria, and the mix of species in that community has a lot to say about your reproductive and pregnancy health. Lactobacillus vaginalis is one of the friendly bacteria that can live there, part of a broader group of Lactobacillus species that keep the local environment acidic and inhospitable to harmful microbes.

Measuring this organism on a vaginal swab gives you a window into whether your vaginal ecosystem is leaning toward a protective, Lactobacillus-dominated state or shifting toward the kind of imbalance linked to bacterial vaginosis, urinary tract issues, sexually transmitted infections, and pregnancy complications. It is one piece of a larger microbial picture, not a stand-alone diagnosis.

What This Test Actually Measures

This swab detects DNA from Lactobacillus vaginalis (a specific Lactobacillus species) on the vaginal lining. Lactobacillus bacteria ferment sugars from vaginal tissue into lactic acid, which pulls vaginal pH into the acidic range of about 3.5 to 4.5 and helps suppress less welcome microbes. The number on your report reflects how much of this one species your sample contained, not your overall Lactobacillus balance or the activity of every species in the community.

Most published research describes the vaginal microbiome at the level of either total Lactobacillus or the four commonly studied species that define the major vaginal community types (L. crispatus, L. iners, L. gasseri, and L. jensenii). Lactobacillus vaginalis is a real but uncommon vaginal colonizer (one landmark study found it in only about 0.3% of women) and is not among these dominant species. Direct evidence about Lactobacillus vaginalis specifically is very limited, so this result is most useful when read alongside other markers from the same swab rather than on its own.

Why Vaginal Lactobacillus Matters

Across diverse populations, a vagina dominated by Lactobacillus species is associated with a lower-risk microbial environment. When Lactobacillus is sparse and anaerobic bacteria like Gardnerella, Prevotella, and Atopobium take over, the risk of bacterial vaginosis, sexually transmitted infections, and dysbiosis rises, especially after menopause. A large epidemiological study of 2,110 women reported that an altered vaginal ecosystem was strongly linked to higher rates of vaginitis, bacterial vaginosis, and sexually transmitted diseases.

In one suppository trial in 66 peri- and premenopausal women with bacterial vaginosis, Lactobacillus vaginalis specifically showed a favorable relationship with itching symptoms after treatment, hinting that this species may track with comfort and recovery during microbiome restoration. The broader evidence base, though, focuses on Lactobacillus as a group rather than on this one species, and this single small trial should be read as preliminary.

Bacterial Vaginosis and Vaginal Dysbiosis

Bacterial vaginosis (BV) is the condition this kind of swab is most often used to investigate. In BV, Lactobacillus species are depleted and anaerobes take over, raising vaginal pH and producing the symptoms many women recognize: discharge, odor, and irritation. Many women also carry asymptomatic BV, where the dysbiosis is present without symptoms but the microbial pattern still looks abnormal.

Molecular vaginal panels that combine Lactobacillus measurements with BV-associated bacteria identify BV with roughly 92 to 95 percent sensitivity and 89 to 96 percent specificity compared with the traditional Nugent score across published studies. That is more precise than older bedside tools like pH or hydrogen peroxide alone, which detect Lactobacillus-dominant flora with high sensitivity but notably poor specificity.

Sexually Transmitted Infections

In a study of 394 reproductive-age women, Trichomonas vaginalis infection was linked to vaginal microbiotas with low proportions of lactobacilli and high proportions of Mycoplasma, Parvimonas, Sneathia, and other anaerobes. Within Lactobacillus, L. iners-dominated communities are more often associated with the transition to BV and STIs than L. crispatus-dominated communities.

This means a low Lactobacillus reading is not just about discharge or odor. It can be an early signal that your vaginal environment is more vulnerable to acquiring or harboring an STI. Pairing this swab with direct STI testing for chlamydia, gonorrhea, and trichomonas gives a clearer picture of both vulnerability and active infection.

HPV, Cervical Lesions, and Cervical Health

A cross-sectional study of 448 women found that high-risk HPV infection and cervical lesions were associated with increased Gardnerella and Prevotella in the vaginal microbiota, alongside reduced Lactobacillus. In a 24-month study of 87 women with untreated CIN2 (a precancerous cervical change), Lactobacillus-dominant baselines were more likely to regress by 12 months, while non-regression tracked with Lactobacillus depletion and overgrowth of Megasphaera, Prevotella timonensis, and Gardnerella vaginalis, after adjusting for age, ethnicity, contraception, douching, smoking, and HPV16/18 status.

Menopause adds another layer. A study of 75 women showed that postmenopausal women with HPV infection had significantly more vaginal dysbiosis than premenopausal women, with more anaerobic bacteria and less Lactobacillus.

Pregnancy and Preterm Birth Risk

A network meta-analysis pooling 17 longitudinal pregnancy cohorts found that women with low-Lactobacillus vaginal communities had about 1.7 times the odds of spontaneous preterm birth compared with those whose vaginas were dominated by L. crispatus (pooled odds ratio 1.69, 95% CI 1.15 to 2.49). A separate cohort of 749 pregnant women showed that depletion of Lactobacillus, especially L. crispatus, and higher overall diversity were linked with higher preterm delivery risk.

In a multicenter cohort of 635 pregnant women, lower Lactobacillus relative abundance at 24 weeks was tied to spontaneous preterm birth. Independent predictors of preterm risk in the same study included prior preterm birth, pH above 4.5, and group B streptococcus positivity, with a combined model achieving moderate predictive accuracy. The takeaway for a pregnant reader is that this swab can flag an at-risk pattern early enough to discuss closer monitoring with an obstetrician.

Fertility and IVF Outcomes

In a large IVF study of 1,411 women undergoing 1,255 embryo transfers, a moderate vaginal Lactobacillus abundance of around 80 percent (especially L. iners and L. crispatus) was associated with higher pregnancy rates, while very high (above 90 percent) Lactobacillus did not appear to improve outcomes further. A population-level study of 6,755 women found that L. iners and L. jensenii dominated communities were linked to higher live birth rates compared with a Fannyhessea vaginae-dominated community (odds ratios of 3.62 and 5.39 respectively).

If you are trying to conceive or planning fertility treatment, this kind of swab can flag whether your vaginal microbiome is in the favorable range or sits at one of the extremes that have been linked to lower implantation odds.

Reading a Lactobacillus Result in Context

Lactobacillus vaginalis is a relatively rare species in the genus, far less studied than the dominant vaginal lactobacilli. L. crispatus tends to be the most protective, while L. iners can show up in both healthy and dysbiotic states. A high reading of any single Lactobacillus species, including L. vaginalis, does not guarantee a balanced microbiome, and a low reading does not necessarily mean dysbiosis if other Lactobacillus species are abundant. The clinical signal comes from the overall composition of the swab, not from one species in isolation.

This is why this test is most useful as part of a vaginal microbiome panel that also reports BV-associated bacteria, total lactobacilli, and pathogens like Trichomonas and Candida. Together they give you the kind of full microbial picture that single-organism tests cannot.

Tracking Your Trend

Vaginal bacteria fluctuate, sometimes dramatically. A daily quantitative PCR study showed that healthy, BV-negative women can see Lactobacillus levels swing by one to four orders of magnitude, especially around menstruation. Across reproductive stages, low-Lactobacillus states often persisted four weeks or more, but day-to-day variability around that baseline is real. No study has published a formal coefficient of variation for Lactobacillus vaginalis specifically.

For these reasons, a single swab is best treated as a snapshot, not a verdict. If you are starting probiotics, recovering from BV treatment, planning pregnancy, or trying to understand recurrent symptoms, get a baseline, then retest in 4 to 12 weeks to see whether the pattern is changing. After that, retesting once or twice a year, or anytime symptoms reappear or you change a medication or contraceptive method, gives you a meaningful trajectory to act on rather than a single data point.

Decision Pathway for an Unexpected Result

If your Lactobacillus vaginalis reading looks low and the broader swab shows Lactobacillus depletion with high BV-associated bacteria, the next steps depend on context. If you have symptoms, the standard pathway is to confirm BV with a clinician and discuss antibiotic treatment. If you are pregnant or trying to conceive, share results with your obstetrician or fertility specialist, since the pattern can influence monitoring and timing of interventions.

If you have no symptoms but the pattern is dysbiotic, useful companion tests include direct STI testing (chlamydia, gonorrhea, trichomonas), HPV testing if you are due for cervical screening, and a Pap smear if not recent. If a high-Lactobacillus result coincides with persistent symptoms, ask about Candida species and other less common causes of vaginitis. Either way, repeating the swab in a few weeks helps confirm whether what you saw is a stable pattern or transient noise.

When Results Can Be Misleading

A single swab can give a distorted picture if collected at the wrong moment. Common sources of distortion include:

  • Menstruation and bleeding: menstruation substantially disrupts the vaginal microbiota, and Lactobacillus species like L. crispatus and L. jensenii commonly drop during menses while Gardnerella rises. Try to sample outside of active bleeding.
  • Recent sex, douching, or vaginal products: intercourse, douching, and intravaginal products like lactic acid gels can shift the microbiome short-term. Lubricating gel used during an exam reduced sample quality enough that a substantial share of gel samples failed processing in one study, although composition of analyzable samples was unchanged.
  • Recent local treatments: vaginal metronidazole rapidly clears BV-associated bacteria, and povidone-iodine used during delivery dose-dependently reduces Lactobacillus. Results within days of these treatments will not reflect your baseline.
  • Copper IUD use: a randomized substudy in 218 women showed copper IUDs increase bacterial diversity, expand inflammatory anaerobes, and decrease vaginal Lactobacillus relative abundance over 1 to 6 months. Hormonal contraceptive methods did not show the same pattern, though one smaller study found no significant change, so the evidence is not unanimous.

Storage matters too. Samples kept at room temperature for more than 48 hours can show significant changes in diversity, while refrigerated storage up to 10 days appears stable. Follow your test provider's instructions for shipping and timing.

What Standard Tests Often Miss

A traditional vaginal exam with a wet mount or Gram stain captures broad categories like Lactobacillus-dominant, intermediate, or BV-pattern flora, but it does not distinguish between Lactobacillus species or quantify them. Symptom-only clinical diagnosis frequently misclassifies BV, Candida, and Trichomonas cases. A molecular swab that reports species-level Lactobacillus alongside BV-associated organisms gives a more precise readout, which is especially valuable if you have recurrent symptoms, unexplained pregnancy losses, fertility concerns, or persistent HPV findings.

That precision comes with a caveat: research on Lactobacillus vaginalis specifically is still thin, and it is a rare vaginal colonizer rather than a dominant species. Interpret your number as one data point in a broader microbial picture, and use trends over time rather than a single reading to guide decisions.

What Moves This Biomarker

Evidence-backed interventions that affect your Lactobacillus Vaginalis level

Increase
Topical metronidazole gel for bacterial vaginosis
Metronidazole gel is the standard treatment for bacterial vaginosis and shifts the vaginal community back toward Lactobacillus dominance, primarily by sharply reducing BV-associated bacteria rather than directly multiplying Lactobacillus. In a randomized substudy of 48 women with BV using 0.75% gel for 5 days, absolute Lactobacillus levels (L. crispatus, L. iners) changed minimally and L. gasseri/jensenii rose less than 1 log10, while BV-associated bacteria dropped 2 to 4 log10 within 24 to 48 hours of finishing treatment. The result is a relative shift toward Lactobacillus dominance, which is what your test will register.
MedicationModerate Evidence
Increase
Oral multi-strain probiotic combined with antibiotics for recurrent BV
Adding a daily oral Lactobacillus probiotic (prOVag) to standard antibiotic therapy increased vaginal Lactobacillus counts and delayed BV recurrence by up to about 51% and aerobic vaginitis recurrence by up to 76% in women with recurrent infections. Dosing was one capsule twice daily for 10 days during antibiotics, then one capsule daily perimenstrually for 10 days per cycle. The shift is visible over months, not days.
SupplementModerate Evidence
Increase
Vaginal Lactobacillus suppositories (multi-strain)
A vaginal probiotic suppository (VagiBIOM) containing L. crispatus, L. gasseri, L. acidophilus, and B. coagulans plus prebiotic, used 5 times weekly for 28 days, significantly reduced vaginal pH and Nugent scores and increased Lactobacillus diversity in peri- and premenopausal women with BV. Lactobacillus vaginalis specifically showed a favorable association with reduced itching after treatment in this trial, one of the few studies reporting on this species. This is a single small trial and should be read as preliminary.
SupplementModerate Evidence
Increase
Oral Lactobacillus gasseri probiotic
Oral L. gasseri CECT 30648 at 10 billion CFU per day for up to 18 days produced a significant reduction in non-Lactobacillus genera and a positive transition toward Lactobacillus-dominated communities in healthy women. The probiotic strain itself was detected in the vagina in 55.9% of participants in the probiotic arm.
SupplementModerate Evidence
Decrease
Copper intrauterine device
In a randomized substudy of 218 women, copper IUD users showed decreased relative abundance of vaginal lactobacilli, increased bacterial diversity, and expansion of inflammatory anaerobes over 1 to 6 months. The same shifts were not seen with hormonal contraceptive methods. A lower Lactobacillus signal here reflects a real ecosystem change toward a dysbiotic, more inflammatory state, not just a measurement artifact. One smaller observational study did not find a significant change, so the evidence is not unanimous, though the larger trial supports this direction.
MedicationModerate Evidence
Decrease
Povidone-iodine antiseptic during delivery
Povidone-iodine applied during delivery produced a dose-dependent decrease in vaginal Lactobacillus relative abundance immediately after delivery, with sharp increases in diversity and expansion of Pseudomonas and Ralstonia. This represents a real, post-procedure shift in the vaginal ecosystem and can persist days to weeks.
MedicationModerate Evidence
Decrease
Hormonal stimulation during IVF and IUI
Across women undergoing fertility treatments, vaginal Lactobacillus percentage generally decreased during cycles of ovarian stimulation, and 9 of 53 women converted from BV-negative to BV-positive by qPCR classification over treatment. The shift can be enough to change BV status, which matters for embryo transfer planning.
MedicationModest Evidence
Increase
Combined oral contraceptive pills in PCOS
In women with polycystic ovary syndrome, 6 months of combined oral contraceptives plus lifestyle coaching was associated with increased relative abundance of vaginal Lactobacillus over 3 to 6 months. Individual trajectories varied, with five distinct patterns observed, and higher baseline testosterone reduced the odds of an increasing-Lactobacillus pattern.
MedicationModest Evidence

Frequently Asked Questions

Panels containing Lactobacillus Vaginalis

Lactobacillus Vaginalis is included in these pre-built panels.

References

60 studies
  1. Muzny C, Blanchard EE, Taylor CM, Aaron KJ, Talluri R, Griswold M, Redden D, Luo M, Welsh D, Van Der Pol WJ, Lefkowitz E, Martin D, Schwebke JThe Journal of Infectious Diseases2018
  2. Brotman R, Bradford L, Conrad MD, Gajer P, Ault K, Peralta L, Forney L, Carlton J, Abdo Z, Ravel JSexually Transmitted Diseases2012
  3. Kim Y, Bergerat-thompson a, Mitchell CPLOS ONE2023
  4. So K, Hur S, Cho C, Lee JK, Seong S, Jeong DH, Ki M, Kim TJScientific Reports2024
  5. Fraszczak K, Barczyński B, Siwiec R, Kondracka a, Malm a, Kotarski J, Witt E, Korona-głowniak IFrontiers in Microbiology2023